Name | Type | Posted | Actions |
|---|---|---|---|
RFP 75A50121R00013 Pages 1-2 9-10-2021.pdf | Sep 10, 2021 | ||
Amendment 4 - Summary.pdf | Sep 10, 2021 | ||
RFP SOW-New Stockpile Updated with Responses 9-2-2021.pdf | Sep 3, 2021 | ||
New Email Account 8-29-2021.pdf | Aug 29, 2021 | ||
Amendment 3 - Past Performance Update v1.pdf | Aug 26, 2021 | ||
Amendment 3 - Past Performance Update.pdf | Aug 25, 2021 | ||
Response - Proposal Ext.pdf | Aug 18, 2021 | ||
QA for Follow-On Stockpile - Additional Questions - 8-16-21 FINAL .pdf | Aug 17, 2021 | ||
QA for Follow Stockpile - IDIQ 8-6-21 FINAL.pdf | Aug 7, 2021 | ||
Amendment 2 - Summary.docx | DOCX | Jul 26, 2021 | |
RFP SOW-New Stockpile 6-29-2021 - Amendment 1.pdf | Jul 23, 2021 | ||
Amendment 1 - Summary.pdf | Jul 23, 2021 | ||
RFP SOW-New Stockpile 6-29-2021 - Program Updated - CLEAN.pdf | Jun 29, 2021 |
Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response
Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response
Contact and place of performance
Wendell Conyers
DC
USA
Reference Amendment 1 PERIOD OF PERFORMANCE a. The base period of performance of this contract is anticipated for thirty-six (36) monthsfrom date of award. The period of performance may be extended up to 24 months withthe exercise of option(s), structured as CLINs. b. If the Government exercises its option(s), the period of performance will be increased as listed below: Option I Twelve (12) Months (Year 4) Option II...
View moreThe Office of the Assistant Secretary for Preparedness and Response, specifically within the BARDA Division of Contracts Management and Acquisition, is soliciting for the acquisition of medical countermeasures to support pandemic influenza and emerging diseases preparedness and response. This requirement is classified under NAICS 325414: Biological Product (except Diagnostic) Manufacturing and PSC 6505: Drugs and Biologicals. The primary scope includes the production of cGMP influenza vaccine master and working seed lots, research and investigational lots, and commercial scale bulk lots of both antigen and adjuvant. Additional services involve formulation and filling into various containers, storage and stability monitoring, the development of potency reagents, and the execution of clinical and non-clinical studies.
The anticipated contract features a 36-month base period of performance, with the potential for two 12-month options that could extend the total duration to five years. Contract activities are centered in Washington, DC, under solicitation number 75A50121R00013. The government provides a minimum guarantee of $50,000.00 for the duration of the award. While many line items require firm-fixed pricing for the base and option years, others—including shipping, analytical laboratory testing, and emerging pathogen activities—will be determined through subsequent Requests for Task Order Response (RTOR).
Responses for this combined synopsis/solicitation are due by September 13, 2021. The notice includes 13 attachments, such as multiple amendments, a revised Statement of Work, and updated past performance instructions. The solicitation also provides for the storage and stability of materials produced under prior contracts and addresses the manufacture of candidate vaccine viruses and disposal of products. Wendall Conyers serves as the point of contact for this requirement.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.